年龄相关性黄斑变性治疗药物研究进展及未来研发方向

Progress in drug treatment development for age-related macular degeneration

年龄相关性黄斑变性是导致老年人失明的主要病因。虽然目前以雷珠单抗为代表的抗血管内皮生长因子(vascular endothelial growth factor,VEGF)药物已经成为年龄相关性黄斑变性的标准治疗药物,但是长期抗VEGF治疗后不仅疗效下降,同时会诱导视网膜纤维化、瘢痕和地图样萎缩等多种并发症,所以开发新的治疗药物单用或者与抗VEGF药物联合应用或者开发多靶点治疗药物成为新的研究方向。目前已经有一些以补体和血小板衍生生长因子为靶点的治疗药物在早期的临床研究中表现出了令人鼓舞的疗效。我们就目前年龄相关性黄斑变性治疗药物研究进展及未来研究方向作一综述。

Age-related macular degeneration （AMD） is a major contributor to blindness in the elderly. Recently, anti-vascular endothelial growth factor antibody drugs, represented by Ranibizumab, have become a standard therapy against AMD;How- ever, after long-term treatment not only therapeutic effects decline, but retinal fibrosis, scarring and geographic atrophy are induced. Thus, the exploration of new drugs used as a mono-therapy or in combination with anti- vascular endothelial growth factor antibody drugs or multi-target drugs is the most hopeful research and development direction in the future. Recently, complement and platelet-derived growth factor-targeting drugs have demonstrated encouraging results during early clinical trials.